Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Allogene Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 171 | 2 | 158 | −11 |
| Shares | 197.1M | 24.8K | 183.6M | −13.5M (−6.8%) |
| Value | $288.5M | $36.2K | $207.9M | −$80.5M (−27.9%) |
2 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Graham Capital Management, L.P. | 302,270 | $341.6K | 0.01% |
| Bourgeon Capital Management LLC | 110,000 | $124.3K | 0.02% |
| Nwi Management LP | 100,000 | $113.0K | 0.01% |
| Acadian Asset Management LLC | 70,466 | $79.0K | 0.00% |
| Los Angeles Capital Management LLC | 35,970 | $40.6K | 0.00% |
| R Squared Ltd | 32,513 | $36.7K | 0.02% |
| Engineers Gate Manager LP | 32,465 | $36.7K | 0.00% |
| Virtu Financial LLC | 24,858 | $28.0K | 0.00% |
| Two Sigma Securities, LLC | 23,039 | $26.0K | 0.00% |
| Investment House LLC | 16,529 | $18.7K | 0.00% |
| Xponance, Inc. | 11,805 | $13.3K | 0.00% |
| Principal Financial Group Inc | 10,382 | $11.7K | 0.00% |
| Fortitude Family Office, LLC | 747 | $844 | 0.00% |
| National Bank of Canada | 467 | $527 | 0.00% |
| Raymond James Financial Inc | 45 | $51 | 0.00% |
| IFP Advisors, Inc | 31 | $35 | 0.00% |
Sold out (27)
Institutions that held Allogene Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (2)
Institutions that held Allogene Therapeutics, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Callan Capital, LLC | 21,089 | $30.8K |
| Lindbrook Capital, LLC | 3,729 | $5.44K |